New research indicates that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who stop traditional lifestyle plans.
Findings released in a prominent health publication demonstrates that while overweight individuals often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Users using such drugs should be informed of the potential of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to original mass within about one and a half years.
Weighing Therapies
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team point out that people who lose weight through lifestyle changes alone usually experience a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the way of the jabs is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means hunger is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
Medical guidelines recommend the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, due to the significant potential of relapse, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who state that the results "emphasize the chronic character of excess weight," similar to managing diseases like high blood pressure.
Patient Accounts
People who have discontinued the jabs report a intense resurgence of appetite.
"It felt as if a trigger that goes on and you become starving," said an individual.
This difficulty is exacerbated if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Use
Survey data suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic cure and maintained weight loss relies on integrated lifestyle management.
